Antares Pharma Appoints John J. Howarth Vice President of Corporate Affairs
27 Fevereiro 2012 - 11:30AM
Business Wire
Antares Pharma, Inc. (NYSE Amex: AIS) today announced the
appointment of John “Jack” Howarth as Vice President of Corporate
Affairs. Mr. Howarth brings to Antares a wealth of knowledge and
leadership in Corporate Affairs garnered from his more than 28
years of experience in the pharmaceutical industry.
“We are very pleased that Jack is joining Antares during this
significant growth period for the Company as we focus on developing
and commercializing drug/device combination products,” said Paul K.
Wotton, Ph.D, President and CEO. “Jack is a seasoned public affairs
executive with expertise in the investor and media relations area
that we expect will complement the existing organization.”
“It’s an exciting time to be joining the Antares team,” said Mr.
Howarth. “Antares has a track record of success, including the
recent FDA approval of Anturol, their oxybutynin 3% gel, coupled
with a diverse and late stage product pipeline with multiple
technologies and a comprehensive patent portfolio, giving Antares
numerous opportunities for growth and an exciting future.”
Mr. Howarth joins Antares from King Pharmaceuticals, where he
served as the Vice President of Investor Relations, joining the
Company through King’s acquisition of Alpharma in 2008. Prior to
this role, Jack held senior leadership positions in investor and
media relations at KOS Pharmaceuticals and Elan Corporation, as
well as positions of increased responsibility in finance and
corporate development during a career spanning almost two decades
at Warner Lambert Company. Mr. Howarth received his B.S. degree in
Accounting from Boston College and his M.B.A. in Finance from Seton
Hall University.
About Antares Pharma
Antares Pharma focuses on self-injection pharmaceutical products
and topical gel-based medicines. The Company's subcutaneous and
intramuscular injection technology platforms include Vibex™
disposable pressure-assisted auto injectors, disposable multi-use
pen injectors and Vision™ reusable needle-free injectors
distributed as Tjet® and Zomajet® by Teva Pharmaceutical
Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring),
respectively. In the injector area, Antares Pharma has a
multi-product deal with Teva that includes Tev-Tropin® human growth
hormone (hGH) and a partnership with Ferring that includes
Zomacton® hGH. In the gel-based area, the Company's FDA approved
product is Anturol® gel, an oxybutynin ATD™ gel for the treatment
of OAB (overactive bladder) which has been licensed to Watson
Pharmaceuticals, Inc. for the U.S. and Canada. Antares’ portfolio
includes Elestrin® (estradiol gel) indicated for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma
has two facilities in the U.S. The Parenteral Products Division
located in Minneapolis, Minnesota directs the manufacturing and
marketing of the Company’s reusable needle-free injection devices
and related disposables, and develops its disposable
pressure-assisted auto injector and pen injector systems. The
Company’s corporate offices and Pharma Division are located in
Ewing, New Jersey, where pharmaceutical products are developed
utilizing both the Company’s transdermal systems and drug/device
combination products.
Antares (AMEX:AIS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Antares (AMEX:AIS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Antares Pharma, Inc. da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Antares Pharma, Inc.